Using partial area for evaluation of bioavailability and bioequivalence

Pharmaceutical Research

Volumn 28, Issue 8, 2011, Pages 1939-1947

  Chen, Mei Ling ^a   Davit, Barbara ^a   Lionberger, Robert ^a   Wahba, Zakaria ^a   Ahn, Hae Young ^a   Yu, Lawrence X ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

bioavailability bioequivalence; early exposure; partial area; partial AUC; truncated area

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; VASODILATOR AGENT; ZOLPIDEM TARTRATE;

BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; HUMANS; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79961173953     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0421-x     Document Type: Review

References (26)

1. U.S. Department of Health and Human Services, Food and Drug Administration. Federal Food, Drug, and Cosmetic Act, as Amended and Related Laws. 86-1051, Section 505 (j) (7)(B); codified as 21 US (U.S. Code) 355 (j)(7)(B). Washington, DC. U.S. Government Printing Office, 1986. p. 66.
2. U.S. Food and Drug Administration. Title 21 Code of Federal Regulations (CFR), Part 320.1, Office of Federal Register, National Archives and Records Administration, U.S. Government Printing Office, Washington, DC, 2010.
3. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. Revised March 2003.
4. SL Nightingale JC Morrison 1987 Generic drugs and the prescribing physicians JAMA. 258 1200 1204 3626003 10.1001/jama.258.9.1200 1:STN:280:DyaL2szht1WgtQ%3D%3D
5. ML Chen LJ Lesko RL Williams 2001 Measures of exposure versus measures of rate and extent of absorption Clin. Pharmacokinet. 40 565 572 11523723 10.2165/00003088-200140080-00001 1:CAS:528:DC%2BD3MXmsl2gsLY%3D (Pubitemid 32758579)
6. TN Tozer FY Bois WW Hauck ML Chen RL Williams 1996 Absorption rate vs. exposure: which is more useful for bioequivalence testing? Pharm. Res. 13 453 456 8692741 10.1023/A:1016061013606 1:CAS:528:DyaK28XhvVOiu7Y%3D (Pubitemid 26112271)
7. ML Chen 1992 An alternative approach for assessment of rate of absorption in bioequivalence studies Pharm. Res. 9 1380 1385 1475222 10.1023/A: 1015842425553 1:CAS:528:DyaK3sXltFyisQ%3D%3D
8. P Macheras M Symillides C Reppas 1994 The cutoff time point of the partial area method for assessment of rate of absorption in bioequivalence studies Pharm. Res. 11 831 834 7937521 10.1023/A:1018921622981 1:CAS:528:DyaK2cXksV2mu7s%3D (Pubitemid 24210616)
9. FY Bois TN Tozer WW Hauck ML Chen R Patnaik RL Williams 1994 Bioequivalence performance of several measures of rate of absorption Pharm. Res. 11 966 974 7937556 10.1023/A:1018970901116 1:CAS:528:DyaK2cXkslejsbk%3D (Pubitemid 24227640)
10. KK Midha JW Hubbard M Rawson L Gavalas 1994 The application of partial areas in assessment of rate and extent of absorption in bioequivalence studies of conventional release products: experimental evidence Eur. J. Pharm. Sci. 2 351 363 10.1016/0928-0987(94)00062-X 1:CAS:528:DyaK2MXjt1Smtrc%3D
11. C Reppas LF Lacey ON Keene P Macheras A Bye 1995 Evaluation of different metrics as indirect measures of rate of drug absorption from extended release dosage forms at steady-state Pharm. Res. 12 103 107 7724468 10.1023/A: 1016246922519 1:CAS:528:DyaK2MXjt12it70%3D
12. L Endrenyi F Csizmadia L Tothfalusi AH Balch ML Chen 1998 The duration of measuring partial AUCs for the assessment of bioequivalence Pharm. Res. 15 399 404 9563068 10.1023/A:1011916113082 1:CAS:528:DyaK1cXisVGru74%3D (Pubitemid 28175119)
13. L Endrenyi F Csizmadia L Tothfalusi ML Chen 1998 Metrics comparing simulated early concentration profiles for the determination of bioequivalence Pharm. Res 15 1292 1299 9706064 10.1023/A:1011912512966 1:CAS:528: DyaK1cXltFynt78%3D (Pubitemid 28401724)
14. A Rostami-Hodjegan PR Jackson GT Tucker 1994 Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies-moving the "goalposts" or changing the "game" J. Pharm. Sci. 83 1554 1557 7891273 10.1002/jps.2600831107 1:CAS:528:DyaK2cXmtlyhtro%3D (Pubitemid 24348324)
15. L Endrenyi L Tothfalusi 1997 Secondary metrics for the assessment of bioequivalence J. Pharm. Sci. 86 3 401 402 9050814 10.1021/js960368n 1:CAS:528:DyaK2sXhtVGhtrc%3D
16. P Macheras M Symillides C Reppas 1996 An improved intercept method for the assessment of absorption rate in bioequivalence studies Pharm. Res. 13 11 1755 1758 8956348 10.1023/A:1016421630290 1:CAS:528:DyaK28XnsVOmt70%3D (Pubitemid 26426906)
17. A Dokoumetzidis P Macheras 2000 On the use of partial AUC as an early exposure metric Eur. J. Pharm. Sci. 10 91 95 10727873 10.1016/S0928-0987(99) 00095-0 1:CAS:528:DC%2BD3cXhvVOqs74%3D (Pubitemid 30155929)
18. Lionberger RA. PK Profile Comparison for Modified Release Products. Presentation at April 2010 Meeting of FDA's Pharmaceutical Science and Clinical Pharmacology Advisory Committee. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM209320.pdf
19. SH Haidar B Davit ML Chen D Conner L Lee QH Li R Lionberger F Makhlouf D Patel DJ Schuirmann LX Yu 2008 Bioequivalence approaches for highly variable drugs and drug products Pharm. Res. 25 237 241 17891552 10.1007/s11095-007-9434- x 1:CAS:528:DC%2BD1cXkslSlsg%3D%3D
20. SH Haidar F Makhlouf DJ Schuirmann T Hyslop B Davit D Conner LX Yu 2008 Evaluation of a scaling approach for the bioequivalence of highly variable drugs AAPS J. 10 450 454 18726698 10.1208/s12248-008-9053-4
21. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Individual Product Bioequivalence Recommendation-Progesterone (Draft guidance). April 2010.
22. ML Chen VP Shah D Ganes KK Midha J Caro P Nambiar, et al. 2010 Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified release products: workshop summary report AAPS J. 12 371 377 20440588 10.1208/s12248-010-9201-5
23. L Tothfalusi S Speidl L Endrenyi 2007 Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets Br. J. Clin. Pharmacol. 65 110 122 17711537 10.1111/j.1365-2125.2007.02984.x (Pubitemid 350265172)
24. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Individual Product Bioequivalence Recommendation-Zolpidem (Draft guidance). August 2009.
25. I Hindmarch E Legangneux N Stanley 2007 A randomized double-blind, placebo-controlled, 10-way cross-over study shows that a new zolpidem modified-release formulation improves sleep maintenance compared to standard zolpidem Sleep. 27 A55
26. T Roth C Soubrane L Titeux JK Walsh 2006 Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia Sleep Medicine. 7 397 406 16815744 10.1016/j.sleep.2006.04.008 (Pubitemid 44103494)